US FDA grants emergency use authorization to sotrovimab for mild-to-moderate Covid-19

Approval of the single-dose monoclonal antibody for use in adults and children aged ≥12 years weighing ≥40kg is based on interim data from the Phase III COMET-ICE trial in high-risk outpatients, which was halted early due to the observed efficacy.

Source:

Biospace Inc.